Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ADXS 506

Next Previous
Drug Profile

ADXS 506

Alternative Names: ADXS 506

Latest Information Update: 28 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advaxis
  • Developer Ayala Pharmaceuticals
  • Class Antineoplastics; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Bladder cancer

Most Recent Events

  • 28 Nov 2023 No recent reports of development identified for preclinical development in Bladder-cancer in USA
  • 19 Jan 2023 Advaxis has merged with Ayala Pharmaceuticals to form Ayala Pharmaceuticals
  • 04 Nov 2019 Advaxis plans to file an IND application with the US FDA in USA for Bladder in the first half of 2020 (Advaxis pipeline, November 2019)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top